A police pursuit in West Virginia turned deadly Thursday afternoon when a driver fleeing in a stolen SUV crashed into another vehicle on Interstate 64, killing a woman who had nothing to do with the ...

Stellantis is relaunching the Jeep Cherokee with hopes to boost a U.S. turnaround. The Cherokee rejoins the compact and midsize vehicle markets after a three-year hiatus and will seek to compete with ...

Jeep’s first electric off-roader is almost here, and it looks like the brand has found a smart way to hide recovery gear where you’d least expect it – tucked inside, not bolted to the bumper. Jeep's ...

WESTLAKE VILLAGE, CA—Welcome back, Jeep. Jeep people themselves won’t deny it: it was a bad move having no competitor in the crucial family SUV segment. The previous Cherokee disappeared a few years ...

Jeep returns the storied Cherokee name to the lineup for 2026 with a fully redesigned compact SUV featuring the brand’s first full-time all-wheel-drive hybrid powertrain as standard. Available in four ...

Jeep is celebrating 85 years of the Wrangler in 2026, and as Stellantis is wont to do, the automaker is rolling out new special edition models every month to commemorate both it and the related ...

Jeep modified the four-door Wrangler to reduce the likelihood of tipping in certain frontal crashes. Wrangler has repeatedly tipped during Insurance Institute for Highway Safety tests in recent years.

When someone mentions the Jeep Cherokee, car people bring up the XJ. It’s inevitable. The XJ wasn’t the first-generation Cherokee; that honor belongs to the old-school SJ, but it became the gold ...

View post: Lamborghini’s 2025 Was Record-Breaking for Sales and Revenue as Profits Slip Signature Autosports built a Jeep Wrangler Rubicon with a 707-hp supercharged Hellcat engine. Upgrades include ...

Once upon a time, Jeep used the Grand Cherokee as a platform for some pretty surprising vehicles. At the top of the list was undoubtedly the SRT and Trackhawk variants, bringing high-performance ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.